A Phase 3 interventional study of Clazakizumab and Physiologic saline solution in Antibody-mediated Rejection, sponsored by CSL Behring. Terminated at 142 sites in 15 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-23.
Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This trial investigates the efficacy and safety of clazakizumab [an anti-interleukin (IL)-6 monoclonal antibody (mAb)] for the treatment of CABMR in recipients of a kidney transplant.
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
First submitted after CSL Behring became part of CSL Limited.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age 18-75 years.
Diagnosis of CABMR determined by kidney and the presence of HLA DSA using single-antigen bead-based assays. For eligibility, kidney biopsy must not be older than 12 months and DSA analysis must be performed no longer than 6 months prior to the start of Screening.
NOTE: • Within 3 months prior to the start of Screening, treatments for ABMR or TCMR, with the exception of *, are not allowed (see Exclusion Criterion 3).
* A maximum dose of 2g of methylprednisolone intravenously (or dose equivalent of other steroids), followed by a taper to the original maintenance steroid dose is allowed.
The following histopathologic and serologic diagnostic criteria (based on Banff 2015 criteria [Loupy et al, 2017]) must be met for inclusion:
i. Linear C4d staining in peritubular capillaries or medullary vasa recta (Banff scores C4d2 or C4d3 by immunofluorescence on frozen sections, or C4d > 0 by immunohistochemistry on paraffin sections).
ii. At least moderate microvascular inflammation ([glomerulitis score, g + peritubular capillaritis score, ptc] ≥ 2) in the absence of recurrent or de novo glomerulonephritis, although in the presence of acute TCMR, borderline infiltrate, or infection, ptc ≥ 2 alone is not sufficient and g must be ≥ 1.
NOTE: The local pathologist's diagnosis must be reviewed by a central pathologist to confirm eligibility for entry into the study. Biopsies with other histopathologic changes (eg, BKV nephropathy or recurrent glomerulonephritis) may be eligible if concurrent CABMR changes (as detailed above) are present and determined to be the predominant cause of renal dysfunction.
c. Serologic evidence of circulating HLA DSA. NOTE: The local laboratory DSA results must be reviewed and confirmed by the central HLA reviewer during the screening period.
Multi-organ transplant recipient (except for simultaneous kidney-pancreas or previous multiple kidney transplants) or cell transplant (islet, bone marrow, stem cell) recipient.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6 that is administered subcutaneously.
Biological: Clazakizumab
Physiologic saline solution that is administered subcutaneously.
Drug: Physiologic saline solution
Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6
Normal saline
Change From Baseline to Week 52 in Estimated Glomerular Filtration Rate (eGFR)
This primary outcome measure was the one from the first interim analysis.
Time frame: From Baseline to Week 52
Number of Participants With Composite All-cause Allograft Loss or Irreversible Loss of Allograft Function
Composite all-cause allograft loss or irreversible loss of allograft function, defined as time to first occurrence of any of the following components: * eGFR \< 15 milliliters per minute per 1.73 square meters (mL/min/1.73 m\^2)\* * return to dialysis\* * allograft nephrectomy * retransplantation * death from any cause, or * a sustained (greater than or equal to \[\>=\] 60 days) 40% decline in eGFR from Baseline. (\*Total cumulative duration of sustained eGFR \< 15 mL/min/1.73 m\^2 AND / OR dialysis \>= 60 days.) If the eGFR \< 15 mL/min/1.73 m\^2 was the only component reached, the value must be sustained over at least 60 days and must be confirmed by a repeat measurement after \>= 60 days from the first measurement. The number of participants with composite all-cause allograft loss or irreversible loss of allograft function are reported here. Time-to-event data were not calculated due to the study's termination.
Time frame: From Baseline to 4 years
Percentage of Participants With Composite All-cause Allograft Loss or Irreversible Loss of Allograft Function
Composite all-cause allograft loss or irreversible loss of allograft function, defined as time to first occurrence of any of the following components: * eGFR \< 15 mL/min/1.73 m\^2\* * return to dialysis\* * allograft nephrectomy * retransplantation * death from any cause, or * a sustained (greater than or equal to \[\>=\] 60 days) 40% decline in eGFR from Baseline. (\*Total cumulative duration of sustained eGFR \< 15 mL/min/1.73 m\^2 AND / OR dialysis \>= 60 days.) If the eGFR \< 15 mL/min/1.73 m\^2 was the only component reached, the value must be sustained over at least 60 days and must be confirmed by a repeat measurement after \>= 60 days from the first measurement. The percentage of participants with composite all-cause allograft loss or irreversible loss of allograft function are reported here.
Time frame: From Baseline to 4 years
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, and Adverse Events of Special Interest (AESIs)
Time frame: Up to 4 years
Percentage of Participants With TEAEs, Serious TEAEs, and AESIs
Time frame: Up to 4 years
Number of Participants Who Tested Positive for Polyoma BK Virus (BKV), Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV)
Number of participants who tested positive for BKV, CMV or EBV according to the maximum measured viral amount (International Units/mL \[IU/mL\]) after baseline are reported here.
Time frame: From baseline up to 4 years
Number of Participants With Abnormal Laboratory Test Results
Laboratory tests included liver function test (LFTs), complete blood count (CBC), plasma lipids, high-sensitivity C-reactive protein (hsCRP). Only participants with abnormal laboratory test results are reported here. Here, ULN = upper limit of normal, LLN = lower limit of normal, ALT = Alanine aminotransferase and AST = Aspartate aminotransferase.
Time frame: Up to 4 years
Percentage of Participants With Abnormal Laboratory Test Results
Laboratory tests included LFTs, CBC, plasma lipids, hsCRP. Only percentage of participants with abnormal laboratory test results are reported here. Here, ULN = upper limit of normal, LLN = lower limit of normal, ALT = Alanine aminotransferase and AST = Aspartate aminotransferase.
Time frame: Up to 4 years
Number of Participants With Clinically Significant Change in Vital Signs, Electrocardiograms (ECGs), and Physical Examination
Time frame: Up to 4 years
Number of Participants With Positive Anti-drug Antibodies
Time frame: Baseline, Weeks 12, 24, and 48
Percentage of Participants With Positive Anti-drug Antibodies
Time frame: Baseline, Weeks 12, 24, and 48
Number of Participants With Composite All-cause Allograft Loss
Composite all-cause allograft loss, defined as, time to first occurrence of any of the following components: * eGFR \< 15 mL/min/1.73 m\^2\* * return to dialysis\* * allograft nephrectomy * retransplantation, or * death from any cause. (\*Total cumulative duration of sustained eGFR \< 15 mL/min/1.73 m\^2 AND / OR dialysis \>= 60 days.) If the eGFR \< 15 mL/min/1.73 m\^2 was the only component reached, the value must be sustained over at least 60 days and must be confirmed by a repeat measurement after \>= 60 days from the first measurement. The number of participants with composite all-cause allograft loss are reported here.
Time frame: From Baseline to 4 years
Percentage of Participants With Composite All-cause Allograft Loss
Composite all-cause allograft loss, defined as, time to first occurrence of any of the following components: * eGFR \< 15 mL/min/1.73 m\^2\* * return to dialysis\* * allograft nephrectomy * retransplantation, or * death from any cause. (\*Total cumulative duration of sustained eGFR \< 15 mL/min/1.73 m\^2 AND / OR dialysis \>= 60 days.) If the eGFR \< 15 mL/min/1.73 m\^2 was the only component reached, the value must be sustained over at least 60 days and must be confirmed by a repeat measurement after \>= 60 days from the first measurement. The percentage of participants with composite all-cause allograft loss are reported here.
Time frame: From Baseline to 4 years
Number of Participants With Irreversible Loss of Allograft Function
Irreversible loss of allograft function as defined by a 40% decline in eGFR from Baseline sustained for at least 60 days.
Time frame: From Baseline to 4 years
Percentage of Participants With Irreversible Loss of Allograft Function
Irreversible loss of allograft function as defined by a 40% decline in eGFR from Baseline sustained for at least 60 days.
Time frame: From Baseline to 4 years
Number of Participants With Death-censored Allograft Loss
Time to death-censored allograft loss, was defined as occurrence of any of the following components: * eGFR \< 15 mL/min/1.73 m\^2\* * return to dialysis\* * allograft nephrectomy, or * retransplantation. (\*Total cumulative duration of sustained eGFR \< 15 mL/min/1.73 m\^2 AND / OR dialysis \>= 60 days.) If the eGFR \< 15 mL/min/1.73 m\^2 was the only component reached, the value must be sustained over at least 60 days and must be confirmed by a repeat measurement after \>= 60 days from the first measurement. The number of participants with death-censored allograft loss are reported here.
Time frame: From Baseline to 4 years
Percentage of Participants With Death-censored Allograft Loss
Death-censored allograft loss was defined as the occurrence of any of the following components: * eGFR \< 15 mL/min/1.73 m\^2\* * return to dialysis\* * allograft nephrectomy, or * retransplantation. (\*Total cumulative duration of sustained eGFR \< 15 mL/min/1.73 m\^2 AND / OR dialysis \>= 60 days.) If the eGFR \< 15 mL/min/1.73 m\^2 was the only component reached, the value must be sustained over at least 60 days and must be confirmed by a repeat measurement after \>= 60 days from the first measurement. The percentage of participants who experienced death-censored allograft loss are reported here.
Time frame: From Baseline to 4 years
Change From Baseline in Urine Albumin Creatinine Ratio (UACR)
Time frame: From Baseline to Week 52
Percent Change From Baseline in Mean Fluorescent Intensity for Donor-Specific Antibodies (DSA)
Time frame: From Baseline to Week 52
Change From Baseline in Banff Lesion Grading Score (2015 Criteria) of Pre-treatment to Post-treatment (Week 52) Kidney Biopsies
Banff lesion grading scores assess the presence and the degree of histopathological changes in the different compartments of kidney biopsies. Here, the improved category is defined as a decline in the Banff lesion grading score. Participants with improved scores, not improved scores, and missing biopsies for C4d staining, interstitial fibrosis, tubular atrophy, glomerular basement membrane double contours, glomerulitis and peritubular capillaritis are reported for this outcome measure.
Time frame: From Baseline to Week 52
Incidence of Acute Rejection Episodes of T Cell-mediated Rejection (TCMR) and Antibody-mediated Rejection (ABMR)
Number of participants who had at least one acute rejection episode (TCMR or ABMR) are reported for this outcome measure.
Time frame: Baseline up to End of treatment (up to approximately 4 years)
Overall Participant Survival
Number of participants who were alive up to Week 52 are reported for this outcome measure.
Time frame: Up to Week 52
Maximum Concentration at Steady State (Cmax ss) of CSL300
A subset of participants (out of the enrolled participants in the main study) had the option to participate in a pharmacokinetic (PK)/ Pharmacodynamic (PD) sub-study.
Time frame: Up to Week 24
Trough Concentrations at Steady State (Ctrough ss) of CSL300
A subset of participants (out of the enrolled participants in the main study) had the option to participate in a PK/PD sub-study.
Time frame: Up to Week 24
Area Under the Concentration-time Curve (AUC0-tau) at Steady State of CSL300
A subset of participants (out of the enrolled participants in the main study) had the option to participate in a PK/PD sub-study.
Time frame: Up to Week 24
Time of Maximum Concentration at Steady State (Tmax ss) of CSL300
A subset of participants (out of the enrolled participants in the main study) had the option to participate in a PK/PD sub-study.
Time frame: Up to Week 24
The study was conducted at 139 study sites in 13 countries: Canada, United States, Austria, Czechia, France, Germany, Hungary, Netherlands, Spain, Sweden, Switzerland, Democratic People's Republic of Korea, and Australia.
| Milestone | Clazakizumab | Placebo |
|---|---|---|
| Started | 94 | 100 |
| Completed | 16 | 15 |
| Not completed | 78 | 85 |
| Withdrew: Withdrew consent | 1 | 8 |
| Withdrew: Physician decision | 5 | 4 |
| Withdrew: Sponsor decision (due to study termination) | 68 | 71 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Other-unspecified | 4 | 1 |
This primary outcome measure was the one from the first interim analysis.
| milliliter per minute per 1.73 meter^2 | Clazakizumab | Placebo |
|---|---|---|
| Change From Baseline to Week 52 in Estimated Glomerular Filtration Rate (eGFR) | -8.0 (-10.2 to -5.8) | -5.2 (-7.4 to -3.1) |
Composite all-cause allograft loss or irreversible loss of allograft function, defined as time to first occurrence of any of the following components: * eGFR \< 15 milliliters per minute per 1.73 square meters (mL/min/1.73 m\^2)\* * return to dialysis\* * allograft nephrectomy * retransplantation * death from any cause, or * a sustained (greater than or equal to \[\>=\] 60 days) 40% decline in eGFR from Baseline. (\*Total cumulative duration of sustained eGFR \< 15 mL/min/1.73 m\^2 AND / OR dialysis \>= 60 days.) If the eGFR \< 15 mL/min/1.73 m\^2 was the only component reached, the value must be sustained over at least 60 days and must be confirmed by a repeat measurement after \>= 60 days from the first measurement. The number of participants with composite all-cause allograft loss or irreversible loss of allograft function are reported here. Time-to-event data were not calculated due to the study's termination.
| Participants | Clazakizumab | Placebo |
|---|---|---|
| Number of Participants With Composite All-cause Allograft Loss or Irreversible Loss of Allograft Function | 26 | 22 |
Composite all-cause allograft loss or irreversible loss of allograft function, defined as time to first occurrence of any of the following components: * eGFR \< 15 mL/min/1.73 m\^2\* * return to dialysis\* * allograft nephrectomy * retransplantation * death from any cause, or * a sustained (greater than or equal to \[\>=\] 60 days) 40% decline in eGFR from Baseline. (\*Total cumulative duration of sustained eGFR \< 15 mL/min/1.73 m\^2 AND / OR dialysis \>= 60 days.) If the eGFR \< 15 mL/min/1.73 m\^2 was the only component reached, the value must be sustained over at least 60 days and must be confirmed by a repeat measurement after \>= 60 days from the first measurement. The percentage of participants with composite all-cause allograft loss or irreversible loss of allograft function are reported here.
| percentage of participants | Clazakizumab | Placebo |
|---|---|---|
| Percentage of Participants With Composite All-cause Allograft Loss or Irreversible Loss of Allograft Function | 28.3 | 22.2 |
| Participants | Clazakizumab | Placebo |
|---|---|---|
| TEAEs | 89 | 88 |
| Serious TEAEs | 39 | 39 |
| AESIs | 56 | 52 |
| percentage of participants | Clazakizumab | Placebo |
|---|---|---|
| TEAEs | 95.7 | 88.0 |
| Serious TEAEs | 41.9 | 39.0 |
| AESIs | 60.2 | 52.0 |
Number of participants who tested positive for BKV, CMV or EBV according to the maximum measured viral amount (International Units/mL \[IU/mL\]) after baseline are reported here.
| Participants | Clazakizumab | Placebo |
|---|---|---|
| BKV >Lower limit of quantification (LLOQ) to <320 IU/mL | 3 | 2 |
| BKV >=320 IU/mL to <3200 IU/mL | 1 | 0 |
| BKV >=3200 IU/mL | 1 | 0 |
| CMV >LLOQ to <1000 IU/mL | 5 | 1 |
| CMV >=1000 IU/mL to <5000 IU/mL | 2 | 2 |
| CMV >=5000 IU/mL | 0 | 0 |
| EBV >LLOQ to <10200 IU/mL | 8 | 7 |
| EBV >=10200 IU/mL to <20400 IU/mL | 0 | 0 |
| EBV >=20400 IU/mL | 0 | 0 |
Laboratory tests included liver function test (LFTs), complete blood count (CBC), plasma lipids, high-sensitivity C-reactive protein (hsCRP). Only participants with abnormal laboratory test results are reported here. Here, ULN = upper limit of normal, LLN = lower limit of normal, ALT = Alanine aminotransferase and AST = Aspartate aminotransferase.
| Participants | Clazakizumab | Placebo |
|---|---|---|
| ALT : >ULN to 3 x ULN | 15 | 6 |
| ALT : > 3 to 5 × ULN | 0 | 1 |
| AST : >ULN to 3 x ULN | 11 | 4 |
| AST : > 3 to 5 × ULN | 1 | 0 |
| AST : > 5 × ULN | 0 | 2 |
| Bilirubin: > ULN to 2 × ULN | 20 | 6 |
| Bilirubin: > 2 × ULN | 5 | 0 |
| Neutrophils: < 2.5 to 1.5 10^9/L | 33 | 21 |
| Neutrophils: < 1.5 to 1.0 10^9/L | 15 | 5 |
| Neutrophils: < 1.0 10^9/L | 7 | 0 |
| Platelets: < LLN to 75.0 10^9/L | 39 | 10 |
| Platelets: < 75.0 to 50.0 10^9/L | 1 | 0 |
Laboratory tests included LFTs, CBC, plasma lipids, hsCRP. Only percentage of participants with abnormal laboratory test results are reported here. Here, ULN = upper limit of normal, LLN = lower limit of normal, ALT = Alanine aminotransferase and AST = Aspartate aminotransferase.
| percentage of participants | Clazakizumab | Placebo |
|---|---|---|
| ALT : >ULN to 3 x ULN | 16.1 | 6.1 |
| ALT : > 3 to 5 × ULN | 0 | 1.0 |
| AST : >ULN to 3 x ULN | 11.8 | 4.0 |
| AST : > 3 to 5 × ULN | 1.1 | 0 |
| AST : > 5 × ULN | 0 | 2.0 |
| Bilirubin: > ULN to 2 × ULN | 21.5 | 6.1 |
| Bilirubin: > 2 × ULN | 5.4 | 0 |
| Neutrophils: < 2.5 to 1.5 10^9/L | 35.5 | 21.2 |
| Neutrophils: < 1.5 to 1.0 10^9/L | 16.1 | 5.1 |
| Neutrophils: < 1.0 10^9/L | 7.5 | 0 |
| Platelets: < LLN to 75.0 10^9/L | 41.9 | 10.1 |
| Platelets: < 75.0 to 50.0 10^9/L | 1.1 | 0 |
| Participants | Clazakizumab | Placebo |
|---|---|---|
| Number of Participants With Clinically Significant Change in Vital Signs, Electrocardiograms (ECGs), and Physical Examination | 0 | 0 |
| Participants | Clazakizumab | Placebo |
|---|---|---|
| Baseline | 5 | 10 |
| Week 12 | 3 | 8 |
| Week 24 | 2 | 7 |
| Week 48 | 0 | 4 |
| percentage of participants | Clazakizumab | Placebo |
|---|---|---|
| Baseline | 5.7 | 10.3 |
| Week 12 | 4.1 | 9.8 |
| Week 24 | 2.9 | 9.7 |
| Week 48 | 0 | 7.7 |
Composite all-cause allograft loss, defined as, time to first occurrence of any of the following components: * eGFR \< 15 mL/min/1.73 m\^2\* * return to dialysis\* * allograft nephrectomy * retransplantation, or * death from any cause. (\*Total cumulative duration of sustained eGFR \< 15 mL/min/1.73 m\^2 AND / OR dialysis \>= 60 days.) If the eGFR \< 15 mL/min/1.73 m\^2 was the only component reached, the value must be sustained over at least 60 days and must be confirmed by a repeat measurement after \>= 60 days from the first measurement. The number of participants with composite all-cause allograft loss are reported here.
| Participants | Clazakizumab | Placebo |
|---|---|---|
| Number of Participants With Composite All-cause Allograft Loss | 17 | 14 |
Composite all-cause allograft loss, defined as, time to first occurrence of any of the following components: * eGFR \< 15 mL/min/1.73 m\^2\* * return to dialysis\* * allograft nephrectomy * retransplantation, or * death from any cause. (\*Total cumulative duration of sustained eGFR \< 15 mL/min/1.73 m\^2 AND / OR dialysis \>= 60 days.) If the eGFR \< 15 mL/min/1.73 m\^2 was the only component reached, the value must be sustained over at least 60 days and must be confirmed by a repeat measurement after \>= 60 days from the first measurement. The percentage of participants with composite all-cause allograft loss are reported here.
| percentage of participants | Clazakizumab | Placebo |
|---|---|---|
| Percentage of Participants With Composite All-cause Allograft Loss | 18.5 | 14.1 |
Irreversible loss of allograft function as defined by a 40% decline in eGFR from Baseline sustained for at least 60 days.
| Participants | Clazakizumab | Placebo |
|---|---|---|
| Number of Participants With Irreversible Loss of Allograft Function | 22 | 18 |
Irreversible loss of allograft function as defined by a 40% decline in eGFR from Baseline sustained for at least 60 days.
| percentage of participants | Clazakizumab | Placebo |
|---|---|---|
| Percentage of Participants With Irreversible Loss of Allograft Function | 23.9 | 18.2 |
Time to death-censored allograft loss, was defined as occurrence of any of the following components: * eGFR \< 15 mL/min/1.73 m\^2\* * return to dialysis\* * allograft nephrectomy, or * retransplantation. (\*Total cumulative duration of sustained eGFR \< 15 mL/min/1.73 m\^2 AND / OR dialysis \>= 60 days.) If the eGFR \< 15 mL/min/1.73 m\^2 was the only component reached, the value must be sustained over at least 60 days and must be confirmed by a repeat measurement after \>= 60 days from the first measurement. The number of participants with death-censored allograft loss are reported here.
| Participants | Clazakizumab | Placebo |
|---|---|---|
| Number of Participants With Death-censored Allograft Loss | 16 | 13 |
Death-censored allograft loss was defined as the occurrence of any of the following components: * eGFR \< 15 mL/min/1.73 m\^2\* * return to dialysis\* * allograft nephrectomy, or * retransplantation. (\*Total cumulative duration of sustained eGFR \< 15 mL/min/1.73 m\^2 AND / OR dialysis \>= 60 days.) If the eGFR \< 15 mL/min/1.73 m\^2 was the only component reached, the value must be sustained over at least 60 days and must be confirmed by a repeat measurement after \>= 60 days from the first measurement. The percentage of participants who experienced death-censored allograft loss are reported here.
| percentage of participants | Clazakizumab | Placebo |
|---|---|---|
| Percentage of Participants With Death-censored Allograft Loss | 17.4 | 13.1 |
| gram per mole | Clazakizumab | Placebo |
|---|---|---|
| Change From Baseline in Urine Albumin Creatinine Ratio (UACR) | 50.734 ± 125.5628 | 31.178 ± 112.8894 |
| percent change | Clazakizumab | Placebo |
|---|---|---|
| DSA Class I | -23.20 (-53.34 to -4.54) | -39.71 (-69.67 to -20.22) |
| DSA Class II | -27.15 (-46.32 to -5.05) | -13.68 (-26.69 to -1.75) |
Banff lesion grading scores assess the presence and the degree of histopathological changes in the different compartments of kidney biopsies. Here, the improved category is defined as a decline in the Banff lesion grading score. Participants with improved scores, not improved scores, and missing biopsies for C4d staining, interstitial fibrosis, tubular atrophy, glomerular basement membrane double contours, glomerulitis and peritubular capillaritis are reported for this outcome measure.
| Participants | Clazakizumab | Placebo |
|---|---|---|
| C4d Staining — Improved score | 10 | 10 |
| C4d Staining — Not improved score | 17 | 21 |
| C4d Staining — Missing biopsies | 65 | 68 |
| Interstitial Fibrosis — Improved score | 3 | 8 |
| Interstitial Fibrosis — Not improved score | 24 | 23 |
| Interstitial Fibrosis — Missing biopsies | 65 | 68 |
| Tubular Atrophy — Improved score | 1 | 5 |
| Tubular Atrophy — Not improved score | 26 | 26 |
| Tubular Atrophy — Missing biopsies | 65 | 68 |
| Glomerular Basement Membrane Double Contours — Improved score | 6 | 10 |
| Glomerular Basement Membrane Double Contours — Not improved score | 21 | 21 |
| Glomerular Basement Membrane Double Contours — Missing biopsies | 65 | 68 |
| Glomerulitis — Improved score | 14 | 17 |
| Glomerulitis — Not improved score | 13 | 14 |
| Glomerulitis — Missing biopsies | 65 | 68 |
| Peritubular Capillaritis — Improved score | 14 | 15 |
| Peritubular Capillaritis — Not improved score | 13 | 16 |
| Peritubular Capillaritis — Missing biopsies | 65 | 68 |
Number of participants who had at least one acute rejection episode (TCMR or ABMR) are reported for this outcome measure.
| Participants | Clazakizumab | Placebo |
|---|---|---|
| Incidence of Acute Rejection Episodes of T Cell-mediated Rejection (TCMR) and Antibody-mediated Rejection (ABMR) | 2 | 3 |
Number of participants who were alive up to Week 52 are reported for this outcome measure.
| Participants | Clazakizumab | Placebo |
|---|---|---|
| Overall Participant Survival | 90 | 98 |
A subset of participants (out of the enrolled participants in the main study) had the option to participate in a pharmacokinetic (PK)/ Pharmacodynamic (PD) sub-study.
| nanograms per milliliter | Clazakizumab |
|---|---|
| Maximum Concentration at Steady State (Cmax ss) of CSL300 | 3556.8 ± 10.5 |
A subset of participants (out of the enrolled participants in the main study) had the option to participate in a PK/PD sub-study.
| nanograms per milliliter | Clazakizumab |
|---|---|
| Trough Concentrations at Steady State (Ctrough ss) of CSL300 | 2366.8 ± 9.2 |
A subset of participants (out of the enrolled participants in the main study) had the option to participate in a PK/PD sub-study.
| days*nanograms per milliliter | Clazakizumab |
|---|---|
| Area Under the Concentration-time Curve (AUC0-tau) at Steady State of CSL300 | 78080.34636 ± 7.19614 |
A subset of participants (out of the enrolled participants in the main study) had the option to participate in a PK/PD sub-study.
| day | Clazakizumab |
|---|---|
| Time of Maximum Concentration at Steady State (Tmax ss) of CSL300 | 6.92292 (4.9986 to 11.9299) |
Collected over Up to 4 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Clazakizumab | 3/93 (3.2%) | 39/93 (41.9%) | 81/93 (87.1%) |
| Placebo | 1/100 (1%) | 39/100 (39%) | 80/100 (80%) |
| Event | Clazakizumab | Placebo |
|---|---|---|
| COVID-19Infections and infestations | 13/93 | 10/100 |
| Acute kidney injuryRenal and urinary disorders | 13/93 | 6/100 |
| DiarrhoeaGastrointestinal disorders | 4/93 | 3/100 |
| PneumoniaInfections and infestations | 3/93 | 1/100 |
| AnaemiaBlood and lymphatic system disorders | 3/93 | 2/100 |
| COVID-19 pneumoniaInfections and infestations | 2/93 | 1/100 |
| Clostridium difficile infectionInfections and infestations | 2/93 | 0/100 |
| Urinary tract infectionInfections and infestations | 2/93 | 0/100 |
| Renal impairmentRenal and urinary disorders | 2/93 | 1/100 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/93 | 0/100 |
| Event | Clazakizumab | Placebo |
|---|---|---|
| COVID-19Infections and infestations | 28/93 | 30/100 |
| Oedema peripheralGeneral disorders | 24/93 | 11/100 |
| DiarrhoeaGastrointestinal disorders | 21/93 | 22/100 |
| AnaemiaBlood and lymphatic system disorders | 16/93 | 16/100 |
| NeutropeniaBlood and lymphatic system disorders | 15/93 | 0/100 |
| HyperkalaemiaMetabolism and nutrition disorders | 12/93 | 13/100 |
| Blood creatinine increasedInvestigations | 9/93 | 13/100 |
| HypertensionVascular disorders | 12/93 | 13/100 |
| Urinary tract infectionInfections and infestations | 12/93 | 6/100 |
| NauseaGastrointestinal disorders | 11/93 | 6/100 |
Analysis was performed on randomized set, which included all participants who were randomized.
| Age, Continuous(years) | Clazakizumab | Placebo | Total |
|---|---|---|---|
| Mean | 46.3 ± 11.87 | 47.0 ± 12.24 | 46.7 ± 12.04 |
| Sex: Female, Male(Participants) | Clazakizumab | Placebo | Total |
|---|---|---|---|
| Female | 29 | 26 | 55 |
| Male | 65 | 74 | 139 |
| Race/Ethnicity, Customized(Participants) | Clazakizumab | Placebo | Total |
|---|---|---|---|
| Ethnicity — Not Hispanic, Latino/a or of Spanish origin | 69 | 78 | 147 |
| Ethnicity — Hispanic, Latino/a or of Spanish origin | 18 | 16 | 34 |
| Ethnicity — Not reported | 5 | 4 | 9 |
| Ethnicity — Unknown | 2 | 2 | 4 |
| Race/Ethnicity, Customized(Participants) | Clazakizumab | Placebo | Total |
|---|---|---|---|
| Race — White | 62 | 69 | 131 |
| Race — Black or African American | 10 | 7 | 17 |
| Race — Korean | 9 | 13 | 22 |
| Race — Other | 6 | 8 | 14 |
| Race — Asian Indian | 3 | 1 | 4 |
| Race — Other Asian | 2 | 1 | 3 |
| Race — American or Alaskan Native | 1 | 0 | 1 |
| Race — Filipino | 1 | 0 | 1 |
| Race — Missing | 0 | 1 | 1 |
Showing the first 100 of 142 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — CSL will consider on a case-by-case basis requests to share Individual Patient Data (IPD) with external bona-fide, qualified scientific and medical researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Requests for IPD will generally be considered once review by major regulatory authorities (ie FDA, EMA) is complete and the primary publication is available.
Access criteria: Proposed research should seek to answer a previously unanswered important medical or scientific question. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.
Ran from Oct 2019 to primary completion in Apr 2024, 53 months.
Results were first posted in Jul 2025, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clazakizumab